Circadian‑driven loss of descending pain inhibition predicts epigenetic age acceleration independent of chronic pain

Hypothesis

Acute pain sensitivity, measured by conditioned pain modulation (CPM) and temporal summation, reflects the integrity of brainstem‑spinal descending inhibitory circuits. When circadian rhythms are disrupted—by nocturnal light exposure, shift work, or sleep fragmentation—these circuits weaken, lowering pain thresholds and increasing facilitation. This weakening parallels a decline in NAD+‑dependent SIRT1 activity in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), which drives epigenetic age acceleration as captured by the Horvath clock. Therefore, a ten‑minute pain sensitivity test can serve as a proxy for biological age in otherwise healthy, pain‑free individuals.

Mechanistic Rationale

• Circadian input to pain modulation: The suprachiasmatic nucleus (SCN) gates glutamatergic tone to the PAG via melatonin‑dependent signaling. Disruption reduces GABAergic inhibition in the PAG, diminishing descending serotonergic and noradrenergic efflux to the dorsal horn, which normally raises pain thresholds (see PubMed 28159611).
• NAD+/SIRT1 link: SIRT1 deacetylates NF‑κB and PGC‑1α, curbing inflammatory transcription and supporting mitochondrial respiration in PAG neurons. Circadian misalignment lowers NAD+ levels, attenuating SIRT1 activity, which has been shown to promote glial activation and cytokine release (see PMC3565621).
• Epigenetic consequence: Reduced SIRT1 leads to increased histone acetylation at promoters of age‑related genes, accelerating DNA methylation drift detected by the Horvath clock (see Frontiers Public Health article).
• Behavioral readout: Weakened descending inhibition manifests as lower CPM efficiency (less pain inhibition during a conditioning stimulus) and greater temporal summation (increased pain to repetitive stimuli). These shifts occur before any clinically evident chronic pain.

Testable Predictions

1. Healthy volunteers subjected to a single night of blue‑light exposure will show a ≥15 % reduction in CPM efficiency and a ≥10 % increase in temporal summation compared to a dark‑night baseline.
2. The magnitude of CPM change will correlate positively with the change in Horvath‑derived epigenetic age measured from buccal swabs taken before and after the light exposure (r > 0.4, p < 0.05).
3. Pharmacological elevation of NAD+ (e.g., nicotinamide riboside supplementation) administered prior to the circadian challenge will attenuate both the pain sensitivity shift and the epigenetic age acceleration.
4. In a longitudinal cohort, baseline CPM efficiency will predict the rate of epigenetic age accrual over 12 months independent of baseline inflammatory markers (CRP, IL‑6).

Experimental Design

• Participants: 60 adults aged 30‑50, free of chronic pain, neurological disease, or shift work.
• Protocol: Within‑subject crossover. Night 1: dim‑light (<5 lux) sleep (control). Night 2: intermittent blue‑light (480 nm, 40 lux) pulses from 02:00–04:00 h. Morning after each night:
  • Pain testing: CPM (cold pressor conditioning stimulus + heat pain test stimulus) and temporal summation (five 49 °C heat pulses).
  • Blood draw for NAD+ metabolites and SIRT1 activity in PBMCs.
  • Buccal swab for Horvath epigenetic age.
• Analysis: Paired t‑tests for CPM/temporal summation changes; linear regression linking ΔCPM to Δepigenetic age; mixed‑effects model for longitudinal prediction.

Potential Confounds & Mitigation

• Sleep deprivation: Control total sleep time with actigraphy; include a sleep‑matched dim‑light condition.
• Expectation bias: Use double‑blind light‑delivery (participants wear goggles that look identical but only the experimental condition transmits blue light).
• Individual differences in melatonin: Measure salivary melatonin to confirm circadian phase shift; include as covariate.
• Exercise or caffeine: Standardize 24 h prior to testing; abstain from vigorous exercise and caffeine 12 h before.

If the predicted relationships hold, a brief, non‑invasive pain sensitivity assay could outperform current multi‑omics clocks as a rapid, functional readout of biological aging, especially in contexts where circadian hygiene is modifiable.